ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 131,41
0,69%
Dow Jones
38 959,89
0,19%
DAX
18 498,38
0,32%
Brent Oil
83,205
0,41%
Bitcoin
62 487,19
0,25%
Registration Strip Icon for alerts Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Biodexa Pharmaceuticals PLC (BDRX)

  7. Biodexa Pharmaceuticals PLC (BDRX) Actualités

BDRX Biodexa Pharmaceuticals PLC

1,06
0,06 (6,00%)
Dernière mise à jour : 18:27:40
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Biodexa Pharmaceuticals PLC BDRX NASDAQ Certificat de dépôt
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
0,06 6,00% 1,06 18:27:40
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
1,01 0,9756 1,11 1,00
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
30/4/202417:51GLOBEBiodexa’s Licensor Emtora to Announce Phase 2 Clinical Trial..
26/4/202414:30GLOBEBiodexa Enters Into Exclusive License to eRapa™, a Phase 3..
19/4/202414:00GLOBEPreliminary Results for the Year Ended 31 December 2023
23/2/202414:30GLOBEBiodexa Announces Positive Top Line Phase I Clinical Trial..
13/2/202414:15APSBiotech Shares Bid Up Premarket Following 9.9% Institutional..
08/2/202414:30GLOBEBiodexa Reports 12 Month Survival in MAGIC-G1 Study of..
07/2/202414:30GLOBEBiodexa Announces Allowance of U.S. Patent Covering..
22/1/202414:30GLOBEBiodexa CEO Issues Shareholder Letter Highlighting Progress..
29/12/202310:05GLOBEBiodexa Appoints Ann Merchant to the Board of Directors
21/12/202322:00GLOBEBiodexa Announces Closing Of $6.0 Million Underwritten..
19/12/202314:42GLOBEBiodexa Announces Pricing of $5.2 Million Underwritten..
27/11/202315:00GLOBEBiodexa Enters Into Agreements to Acquire Exclusive..
03/10/202314:30GLOBEBiodexa Completes Recruitment of Cohort A in Study of MTX110..
29/9/202322:30GLOBEInterim results for the six months ended 30 June 2023
21/9/202314:30GLOBEBiodexa to Present Recruitment and Treatment Update in ..
28/7/202314:00GLOBEBiodexa Pharmaceuticals Launches New Corporate and Clinical..
24/7/202313:30GLOBEBiodexa Regain Compliance with NASDAQ Minimum Bid Price..
10/7/202314:00GLOBECompletion of Enrolment and Treatment in the Phase 1 Study..
06/7/202322:30GLOBEResults of Appeal of Delisting Determination
06/7/202314:15GLOBEPublication of Manuscript from the PNOC015 (a.k.a. MTD-201)..
22/6/202322:15GLOBEADR Ratio Change
20/6/202314:00GLOBEAppeal of Delisting Determination
15/6/202322:05GLOBEReceipt of NASDAQ Delisting Determination Plans to Appeal
14/6/202314:30GLOBEResults of Annual General Meeting and General Meeting
26/5/202322:05GLOBEBiodexa Pharmaceuticals PLC Announces Closing of $3.32..
24/5/202314:40GLOBEBiodexa Pharmaceuticals PLC Announces US$3.32 Million..
22/5/202322:15GLOBEPosting of Annual Report & Notice of AGM
18/5/202314:30GLOBEBiodexa Pharmaceuticals Enters into Non-binding Letter of..

Dernières Valeurs Consultées

NASDAQ
BDRX
Biodexa Pharmaceuticals
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés